Alteogen’s NexP™ Fusion Technology is a second-generation platform that uses recombinant human A1AT (alpha-1 antitrypsin), a protein abundant in human blood, as a protein carrier to increase the half-life of biopharmaceuticals in the body.

A1AT has been used for years as a treatment for emphysema, and its safety has already been proven.

• *Increased in vivo persistence
• *Elimination of intrinsic protein activity

By removing the intrinsic activity of the A1AT protein using Alteogen’s NexP™ fusion technology, it becomes an even safer carrier. When fused with therapeutic proteins or peptides, it does not interfere with the drug’s activity while maintaining a longer duration in the body compared to other long-acting technologies.

Non-clinical pharmacokinetic and pharmacodynamic studies of test protein drugs developed using NexP™ fusion technology have shown a significant increase in in vivo half-life and improved potency, resulting in reduced dosing frequency, decreased side effects, and enhanced clinical efficacy.

In addition, NexP™ fusion technology can be applied to both the C-terminus and N-terminus of therapeutic proteins or peptides, making it Alteogen’s core platform technology for the development of next-generation long-acting biopharmaceuticals.